tetano
Editor, Senior Moderator
BMC Med
. 2023 Apr 11;21(1):139.
doi: 10.1186/s12916-023-02853-3.
The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016
Jocelyn Moyes[SUP] 1 2 [/SUP], Stefano Tempia[SUP] 3 [/SUP], Sibongile Walaza[SUP] 3 4 [/SUP], Meredith L McMorrow[SUP] 5 [/SUP], Florette Treurnicht[SUP] 6 [/SUP], Nicole Wolter[SUP] 3 7 [/SUP], Anne von Gottberg[SUP] 3 7 [/SUP], Kathleen Kahn[SUP] 8 [/SUP], Adam L Cohen[SUP] 9 10 [/SUP], Halima Dawood[SUP] 11 12 [/SUP], Ebrahim Variava[SUP] 13 14 15 [/SUP], Cheryl Cohen[SUP] 16 17 [/SUP]
Affiliations
Abstract
Background: Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses.
Methods: We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged < 5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the < 1-year age group, by 3-month intervals until 2 years, and then 12 monthly intervals to < 5 years for medically and non-medically attended illness.
Results: We estimated a mean annual total (medically and non-medically attended) of 264,112 (95% confidence interval (CI) 134,357-437,187) cases of RSV-associated ARI and 96,220 (95% CI 66,470-132,844) cases of RSV-associated SARI (4.7% and 1.7% of the population aged < 5 years, respectively). RSV-associated ARI incidence was highest in 2-month-old infants (18,361/100,000 population, 95% CI 9336-28,466). The highest incidence of RSV-associated SARI was in the < 1-month age group 14,674/100,000 (95% CI 11,175-19,645). RSV-associated deaths were highest in the first and second month of life (110.8 (95% CI 74.8-144.5) and 111.3 (86.0-135.8), respectively).
Conclusions: Due to the high burden of RSV-associated illness, specifically SARI cases in young infants, maternal vaccination and monoclonal antibody products delivered at birth could prevent significant RSV-associated disease burden.
Keywords: Burden; Children; Respiratory illness; Respiratory syncytial virus.
. 2023 Apr 11;21(1):139.
doi: 10.1186/s12916-023-02853-3.
The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016
Jocelyn Moyes[SUP] 1 2 [/SUP], Stefano Tempia[SUP] 3 [/SUP], Sibongile Walaza[SUP] 3 4 [/SUP], Meredith L McMorrow[SUP] 5 [/SUP], Florette Treurnicht[SUP] 6 [/SUP], Nicole Wolter[SUP] 3 7 [/SUP], Anne von Gottberg[SUP] 3 7 [/SUP], Kathleen Kahn[SUP] 8 [/SUP], Adam L Cohen[SUP] 9 10 [/SUP], Halima Dawood[SUP] 11 12 [/SUP], Ebrahim Variava[SUP] 13 14 15 [/SUP], Cheryl Cohen[SUP] 16 17 [/SUP]
Affiliations
- PMID: 37038125
- DOI: 10.1186/s12916-023-02853-3
Abstract
Background: Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses.
Methods: We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged < 5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the < 1-year age group, by 3-month intervals until 2 years, and then 12 monthly intervals to < 5 years for medically and non-medically attended illness.
Results: We estimated a mean annual total (medically and non-medically attended) of 264,112 (95% confidence interval (CI) 134,357-437,187) cases of RSV-associated ARI and 96,220 (95% CI 66,470-132,844) cases of RSV-associated SARI (4.7% and 1.7% of the population aged < 5 years, respectively). RSV-associated ARI incidence was highest in 2-month-old infants (18,361/100,000 population, 95% CI 9336-28,466). The highest incidence of RSV-associated SARI was in the < 1-month age group 14,674/100,000 (95% CI 11,175-19,645). RSV-associated deaths were highest in the first and second month of life (110.8 (95% CI 74.8-144.5) and 111.3 (86.0-135.8), respectively).
Conclusions: Due to the high burden of RSV-associated illness, specifically SARI cases in young infants, maternal vaccination and monoclonal antibody products delivered at birth could prevent significant RSV-associated disease burden.
Keywords: Burden; Children; Respiratory illness; Respiratory syncytial virus.